Beraud Jill — SEC insider filings
SEC reporting owner CIK 1520061. 37 insider filings on record with FilingPulse; latest filed 2026-11-06.
Transaction summary — filings shown
Covers all 37 filings on record, filed 2021-03-02 to 2026-11-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 63.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| LEVI STRAUSS & CO (LEVI) | Director | 31 | — | — | 52 |
| Revance Therapeutics, Inc. (RVNC) | Director | 6 | — | — | 11 |
Insider filings — Beraud Jill
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-06 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 57 @ $0 · Grant/award (A): 97 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 54 @ $0 · Grant/award (A): 92 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 50 @ $0 · Grant/award (A): 86 (derivative) @ $0 | EDGAR |
| 2026-04-24 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 8,381 @ $0 | EDGAR |
| 2026-02-27 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 75 @ $0 · Grant/award (A): 89 (derivative) @ $0 | EDGAR |
| 2025-11-06 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 85 @ $0 · Grant/award (A): 101 (derivative) @ $0 | EDGAR |
| 2025-08-12 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 82 @ $0 · Grant/award (A): 97 (derivative) @ $0 | EDGAR |
| 2025-05-12 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 88 @ $0 · Grant/award (A): 104 (derivative) @ $0 | EDGAR |
| 2025-04-25 | 4 | LEVI STRAUSS & CO (LEVI) | Conversion (C): 108,679 @ $0 · Grant/award (A): 11,690 @ $0 · Conversion (C): 108,679 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 56 @ $0 · Grant/award (A): 99 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Revance Therapeutics, Inc. (RVNC) | Code (U): 28,606 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2024-11-18 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 60 @ $0 · Grant/award (A): 106 (derivative) @ $0 | EDGAR |
| 2024-08-22 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 52 @ $0 · Grant/award (A): 93 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 42 @ $0 · Grant/award (A): 74 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 15,000 @ $0 · Grant/award (A): 23,458 (derivative) @ $0 | EDGAR |
| 2024-04-26 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 7,642 @ $0 | EDGAR |
| 2024-02-27 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 69 @ $0 · Grant/award (A): 88 (derivative) @ $0 | EDGAR |
| 2023-11-13 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 87 @ $0 · Grant/award (A): 112 (derivative) @ $0 | EDGAR |
| 2023-08-21 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 88 @ $0 · Grant/award (A): 113 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 129 @ $0 · Grant/award (A): 117 (derivative) @ $0 | EDGAR |
| 2023-05-05 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 3,534 @ $0 · Grant/award (A): 5,915 (derivative) @ $0 | EDGAR |
| 2023-04-21 | 4/A | LEVI STRAUSS & CO (LEVI) | Other (J): 77,410 @ $0 · Other (J): 43,330 @ $0 · Other (J): 77,410 (derivative) @ $0 · Other (J): 43,330 (derivative) @ $0 | EDGAR |
| 2023-04-21 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 10,251 @ $0 | EDGAR |
| 2023-02-27 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 87 @ $0 · Grant/award (A): 81 @ $0 | EDGAR |
| 2022-11-23 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 190 @ $0 | EDGAR |
| 2022-08-18 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 152 @ $0 | EDGAR |
| 2022-05-25 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 222 @ $0 | EDGAR |
| 2022-05-13 | 4/A | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 10,756 (derivative) @ $0 | EDGAR |
| 2022-05-06 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 6,059 @ $0 · Grant/award (A): 11,343 (derivative) @ $0 | EDGAR |
| 2022-04-22 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 7,812 @ $0 | EDGAR |
| 2022-02-28 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 129 @ $0 | EDGAR |
| 2021-11-18 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 81 @ $0 | EDGAR |
| 2021-09-02 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 94 @ $0 | EDGAR |
| 2021-07-19 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 5,455 @ $0 | EDGAR |
| 2021-05-26 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 72 @ $0 | EDGAR |
| 2021-05-07 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 4,013 @ $0 · Grant/award (A): 7,551 (derivative) @ $0 | EDGAR |
| 2021-03-02 | 4 | LEVI STRAUSS & CO (LEVI) | Grant/award (A): 56 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-03-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1520061 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs